Trial review reports progression-free survival outcomes for amivantamab and lazertinib in untreated EGFR-mutated lung cancer, highlighting a potential alternative to front-line osimertinib.
Osimertinib is the current first-line treatment for EGFR-mutated NSCLC, however, patients frequently relapse due to acquired resistance mutations.Amivantamab is a bispecific antibody against EGFR and MET alterations.Lazertinib is a tyrosine kinase inhibitor active against EGFR mutations including common resistance mutations.The MARIPOSA trial was designed to study if the combination of amivantamab plus lazertinib in untreated epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients would provide improved progression-free survival.Here, we discuss the rationale for the study and the early results of MARIPOSA.
No takes yet. Share an insight, caveat, or question.
Brazel et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: